Translational Awards

To support the early stage development of new cardiovascular medicines and technologies so that they are attractive for follow-on funding.

The award will help to bridge the funding gap between promising innovations and the clinic with the aim of accelerating advances in cardiovascular science for patient benefit.

Please note that we have made changes to the Translational Award and have increased the maximum allowable budget for the overall project to £750,000.

Entry requirements

  • The principal investigator will be a senior researcher working in an established research institution in the UK.

Award specifications

  • The award can be used for all types of development, such as therapeutics (novel / repurposed), devices, imaging technologies, diagnostics, computer models and algorithms.
  • Your project should be novel, inventive and address an unmet clinical need.
  • Your project should not be addressing a fundamental scientific hypothesis.
  • Your project should include:
    • Robust target validation data
    • Non-overlapping milestones each with a clear go/no-go decision (progress will be assessed at each milestone, with continuation of funding subject to approval – see ‘Project management and reporting below’ below)
    • A strategy to navigate the regulatory process
    • A proposed route to market
    • An understanding of the Intellectual Property (IP) landscape

The maximum allowable budget is £750,000 for the overall project with clear identified milestones and the cost for each milestone identified and justified. If BHF is the most appropriate follow on funder, we may provide further support beyond the Translational Award. This will be considered on a case by case basis.

The BHF and your institution's Technology Transfer Office (TTO) are able to provide advice on your application. A project with potential can be developed between the preliminary outline and full application with guidance from our Translational Awards Committee.

If you are unsure whether your research is at the appropriate stage or is eligible for funding, please contact a member of the team at [email protected].

Award may include

The award can be used flexibly to advance the medicine or technology in the most effective manner. For example, it can be used for staff salaries (excluding PhD studentships), consumables and essential research equipment, IP consultancy fees, outsourcing to contract research organisations and relevant training courses.

Longer term project goals

In your application, it is important to consider the entire route to commercialisation for your technology and not just what will be funded by this particular Translational Award.

Providing this information gives the BHF and subsequent investors the confidence that the project is well designed and has the best chance of success.

The MHRA Innovation Office provides a free, informal service that can help with your regulatory queries. 

Hear from the experts

We previously held a workshop, ‘How to Translate your Research’. Committee members and industry experts discussed what they look for in a good project. Highlights are included in the video below:


How to apply

Applications are assessed in a two-stage process:

Preliminary outline applications

The first step involves review of an outline application by the Translational Awards Committee (meets twice a year). The Committee will provide advice about the suitability of your project for the award and review whether your proposal is likely to lead to a clinical impact.

Please complete the Outline Application Form referring to Translational Award Outline Application Guidelines and Translational Award Terms & Conditions. Applications must be completed in partnership with your institution's TTO. 

Please note that appendices should be a maximum of 2 additional A4 pages containing tables, figures and key references essential to the understanding of the application. Research papers whether published, in press or in preparation may not be attached (although hyperlinks can be provided).

Full applications

Successful outline applicants will be asked to complete a full application form. Your full application will be reviewed by external peer review and by the Translational Awards Committee. Full applications will be reviewed in detail on scientific merit and on commercial viability.

Specific guidance for preparation of full applications will be provided along with outline application feedback. If your proposal includes animal work or human tissue, please complete a questionnaire on experiments on animals form (EXA) or a questionnaire on experiments involving human subjects form (EXH) as necessary.

Decision process

There are two application rounds a year and the deadline dates are below. Applications must be received by midday. Late submissions will not be considered.

Outline and full applications will be reviewed at Committee meetings. If your outline application is approved; you are invited to submit a full application, which will be assessed at the next meeting.   

April 2018 round

  • Preliminary outline application deadline -23rd April 2018
  • Full application deadline –5th September 2018

October 2018 round

  • Preliminary outline application deadline -15th October 2018
  • Full application deadline – 6th March 2019

April 2019 round

  • Preliminary outline application deadline -15th April 2019
  • Full application deadline –11th September 2019

We will acknowledge receipt of your application within 1 working week and we will advise when you can expect the result. BHF reserve the right to change the deadline dates and we recommend that you check this page on a regular basis to take note of any changes.

Please allow 7 months from submission to decision.

Project management and reporting

Successful Translational Awards require efficient management and reporting to ensure that the project stays on target and a project manager may be appointed by the BHF to assist with this. On completion of each milestone period, a written progress report should be submitted and will be reviewed by selected members of the Translational Awards Committee (additional discussion, in face-to-face meeting(s) and/or through telephone or Skype call(s), may be requested), who will indicate whether the milestone has been met satisfactorily. Continuation or cessation of funding for work towards subsequent milestone(s) is subject to such assessment and, where necessary, decisions will be taken by Chair’s action outside of the Committee meetings schedule, to avoid delay.